Akebia Therapeutics Inc

Akebia Therapeutics, Inc. (www.akebia.com) is a biopharmaceutical company. The Company is focused on producing medicines for people living with kidney disease. Its lead product candidate, vadadustat, is an oral therapy in development for the treatment of anemia due to chronic kidney disease (CKD). Vadadustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), designed to mimic the physiologic effect of altitude on oxygen availability. In addition, it has a commercial product, Auryxia (ferric citrate), which is marketed for two indications in the United States: the control of serum phosphorus levels in dialysis-dependent (DD)-CKD adult patients and the treatment of iron deficiency anemia (IDA), in non-dialysis dependent (NDD)-CKD adult patients. Ferric citrate is also approved and marketed in Japan as an oral treatment for the improvement of hyperphosphatemia in patients with CKD.

• Akebia Therapeutics Inc